Abstract
This study uses Scientometric analysis to review Sigesbeckiae Herba (SH) research worldwide from 1980 to 2024. Data-driven analysis identifies patterns, partnerships, and possibilities. Due to its wide profile and traditional medical uses, SH is gaining attention, according to this research. China has made the most important contributions to SH research, followed by the United stated of America and Korea. Countries and organizations have not collaborated on SH research. We found "anti-inflammation," "rheumatic arthritis," and "NF-κβ" using keyword co-occurrence analysis. Citation analysis showed SH research's most prominent institutions, journals, and authors, offering a complete snapshot of organization and diffusion. The data shows that this subject has received substantial academic interest despite a reduction in publications since 2019. These findings highlight the need for cooperation, multidisciplinary methods, and attention to underrepresented disciplines for academics, funding organizations, and policymakers. SH has been used to cure inflammation. Sigesbeckia orientalis L., S. pubescens Makino, and S. glabrescens Makino are the primary botanical sources. This research extensively evaluates SH literature, focusing on its botanical properties, bioactive components, pharmacological effects, and probable toxicity. More than three hundred phytochemicals, including flavonoids, diterpenoids, sesquiterpenoids, oxylipins, and lignoids, were identified in the extract, many of which are known to exert diverse biological effects. The extracts of SH are used in traditional Chinese medicine (TCM) due to its immunomodulatory, anti-inflammatory, and anti-cancer activities and are being considered for cosmetics and skin issues. Pharmacological benefits of diterpenoids, sesquiterpenoids, and flavonoids are found. The study recommends further research and cooperation to enhance TCM and herbal research by comparing the chemical and pharmacological properties of these three SH species.